Cognito Therapeutics Presents New Biomarker Findings Highlighting Potential Mechanism of Spectris™ Neuromodulation for Alzheimer’s Disease
Cognito Therapeutics, a clinical-stage neurotechnology company focused on developing innovative therapies for neurodegenerative diseases, has unveiled new exploratory biomarker findings that provide additional insight into how its investigational Spectris™ neuromodulation platform may influence the underlying biology of Alzheimer’s disease. The data were presented at the Alzheimer’s Association International Conference (AAIC) 2026, one of the world’s leading scientific meetings dedicated to dementia research.
The newly presented results come from an exploratory cerebrospinal fluid (CSF) proteomics analysis conducted as part of the company’s Phase 2 FLICKER clinical study involving patients with amyloid-positive mild cognitive impairment (MCI), an early stage of Alzheimer’s disease. The findings suggest that Spectris therapy may activate biological pathways associated with lipid transport, myelin maintenance, and overall brain health, offering researchers additional evidence supporting the platform’s potential neuroprotective effects.
Advancing the Understanding of Alzheimer’s Disease
Alzheimer’s disease remains one of the greatest unmet medical challenges worldwide. While several therapies have recently targeted amyloid pathology, researchers increasingly recognize that the disease involves multiple interconnected biological processes, including inflammation, neuronal dysfunction, synaptic loss, impaired lipid metabolism, and deterioration of white matter.
Cognito Therapeutics is pursuing a different treatment strategy through non-invasive neuromodulation designed to influence brain activity using precisely synchronized sensory stimulation. Rather than directly targeting amyloid plaques or tau proteins through drugs, the Spectris platform seeks to modulate neural circuits that may help preserve brain function and slow disease progression.
The latest biomarker analysis provides additional evidence that this approach may produce measurable biological changes within the central nervous system.
Exploratory Proteomics Analysis Reveals Significant Biological Changes
The poster presentation, titled “Spectris™ Sensory Stimulation Increases CSF HDL-Like Lipid Transport Proteins in Alzheimer’s Disease,” describes findings obtained using an unbiased mass spectrometry-based proteomics approach.
Instead of focusing on a predefined set of biomarkers, investigators analyzed hundreds of proteins present in cerebrospinal fluid to identify treatment-related changes after patients received daily Spectris therapy.
According to the analysis, participants treated with Spectris demonstrated increased levels of several important HDL-like lipid transport proteins, including:
- APOA1
- APOA2
- APOL1
These proteins play important roles in lipid transport, cholesterol regulation, and neuronal maintenance within the brain.
Researchers noted that these changes were not isolated observations. Instead, pathway analysis revealed that 13 of the 29 significantly upregulated biological pathways were associated with lipid transport or lipid metabolism. This coordinated pattern suggests that Spectris therapy may influence broader biological networks rather than affecting only individual proteins.
Importance of Lipid Transport in Alzheimer’s Disease
Lipid metabolism has become an increasingly important area of Alzheimer’s research.
The human brain contains large amounts of cholesterol and specialized lipids that are essential for maintaining neuronal membranes, synaptic communication, and myelin integrity. Disruptions in lipid transport have been linked to cognitive decline and neurodegeneration.
Proteins such as APOA1 have attracted considerable scientific interest because previous research has shown associations between higher cerebrospinal fluid APOA1 concentrations and healthier neurological function.
Published studies have also reported inverse relationships between CSF APOA1 levels and phosphorylated tau (pTau181), one of the key biomarkers associated with Alzheimer’s disease progression.
The appearance of these proteins through an unbiased screening process strengthens the biological relevance of the findings and provides investigators with additional targets for future clinical research.
Evidence of Myelination Pathway Activation
Beyond lipid metabolism, the study identified another important biological signal.
Investigators observed significant enrichment of the Oligodendrocyte/Myelination (M36) co-expression module, a pathway involved in maintaining myelin and white matter integrity.
Myelin acts as an insulating layer around nerve fibers, allowing electrical signals to travel efficiently throughout the brain. Damage to myelin and deterioration of white matter have been increasingly recognized as contributing factors in Alzheimer’s disease and age-related cognitive decline.
Preserving myelin may therefore play an important role in maintaining healthy cognitive function.
The newly reported proteomics findings align with previous imaging observations from Cognito’s OVERTURE feasibility study, which suggested that Spectris treatment may help preserve white matter structure over time.
Together, the imaging and proteomic data provide complementary evidence supporting a possible biological mechanism involving both neuronal communication and structural brain preservation.
Insights from the FLICKER Phase 2 Study
The exploratory analysis was performed using cerebrospinal fluid samples collected during the company’s Phase 2 FLICKER clinical trial.
The study enrolled 10 participants diagnosed with amyloid-positive mild cognitive impairment, representing individuals in the earliest clinically detectable stages of Alzheimer’s disease.
Participants received one hour of daily Spectris sensory stimulation using a delayed-start study design.
Treatment duration consisted of either:
- Eight weeks of daily therapy
- Four weeks of therapy following delayed treatment initiation
Cerebrospinal fluid samples were collected at three time points:
- Baseline
- Week 4
- Week 8
Researchers then applied unbiased tandem mass spectrometry to evaluate changes in protein expression associated with treatment.
Although the sample size was relatively small and the analyses remain exploratory, the results generated several biologically meaningful hypotheses that can be evaluated in larger clinical trials.
Scientific Perspective from Cognito Therapeutics
Christian Howell, Chief Executive Officer of Cognito Therapeutics, emphasized that each new dataset contributes to a deeper understanding of how non-invasive neuromodulation may affect Alzheimer’s disease biology.
He explained that the identification of coordinated lipid transport and myelination pathways supports the company’s scientific hypothesis regarding the Spectris platform.
According to Howell, while these findings should be interpreted cautiously because they are exploratory, they provide valuable direction for future research and justify incorporating these biomarkers into larger clinical studies.
He also noted that understanding the biological mechanisms behind Spectris therapy is an important step toward developing a new class of neuroprotective treatments capable of addressing multiple aspects of Alzheimer’s disease rather than focusing solely on amyloid pathology.
Building a Broader Evidence Base
The newly presented findings add to an expanding body of evidence surrounding the Spectris platform.
Earlier studies have suggested that synchronized sensory stimulation may influence neural network activity, potentially restoring brain oscillations that become disrupted during Alzheimer’s disease.
The current proteomics data extend those observations by demonstrating measurable molecular changes occurring within cerebrospinal fluid.
Importantly, the overlap between protein pathway findings and previous MRI observations strengthens confidence that multiple independent assessment methods may be detecting related biological effects.
Such convergence across different biomarkers is considered valuable in neurodegenerative disease research because Alzheimer’s pathology is complex and unlikely to be fully explained by any single measurement.
Future Clinical Development
Cognito Therapeutics plans to continue evaluating these newly identified biomarkers in future clinical studies involving larger patient populations.
The company intends to investigate whether changes in lipid transport proteins, myelination pathways, and other molecular markers correlate with improvements in cognition, disease progression, imaging outcomes, and long-term clinical benefit.
Future trials are expected to include these biomarkers as pre-specified endpoints, allowing researchers to determine whether they can serve as reliable indicators of treatment response.
If confirmed in adequately powered studies, these biomarkers could help explain the mechanism through which Spectris exerts its effects while also supporting the development of personalized treatment strategies for Alzheimer’s disease.
Expanding the Potential of Non-Invasive Neuromodulation
The presentation at AAIC 2026 represents another milestone in Cognito Therapeutics’ effort to establish scientific evidence for non-invasive neuromodulation as a potential therapeutic approach for neurodegenerative diseases.
Unlike conventional pharmaceutical therapies, Spectris delivers precisely controlled sensory stimulation designed to influence brain activity without invasive procedures or systemic drug exposure.
While additional clinical validation remains necessary, the emerging biological evidence suggests that this approach may affect several interconnected mechanisms involved in Alzheimer’s disease, including lipid metabolism, white matter preservation, and neuronal health.
As research continues, the integration of molecular biomarkers, neuroimaging findings, and clinical outcomes will be critical in determining the long-term therapeutic potential of the Spectris platform. The latest exploratory findings provide an encouraging scientific foundation for that ongoing work and support continued investigation into non-invasive neuromodulation as a possible strategy for slowing or modifying the progression of Alzheimer’s disease.
About Cognito Therapeutics
Cognito Therapeutics is a late clinical-stage neurotechnology company pioneering neuroprotective therapies to address the unmet needs of patients living with CNS disorders and support broader brain health. Its lead product, Spectris™, is an investigational at-home neuroprotective therapy platform that uses non-invasive, sensory-driven neurostimulation to evoke gamma frequency brain activity. The company’s feasibility studies have shown the potential for Spectris to preserve cognition, daily function, and slow brain atrophy in patients diagnosed with mild-to-moderate AD. Cognito is headquartered in Cambridge, MA.